Targeting thromboinflammation in antiphospholipid syndrome
Journal of Thrombosis and Haemostasis · 2023-04 · 21 (4) · 744-757
DOI: 10.1016/j.jtha.2022.12.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-04. Verfasst von Dorien M Salet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands. Electronic address: d.salet@amsterdamumc.nl. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Thrombosis. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antiphospholipid syndrome (APS) is a systemic autoimmune disease, where persistent presence of antiphospholipid antibodies (aPL) leads to thrombotic and obstetric complications. APS is a paradigmatic thromboinflammatory disease. Thromboinflammation is a pathophysiological mechanism coupling inflammation and thrombosis, which contributes to the pathophysiology of cardiovascular disease. APS can serve as a model to unravel mechanisms of thromboinflammation and the relationship between innate immune cells and thrombosis. Monocytes are activated by aPL into a proinflammatory and procoagulant phenotype, producing proinflammatory cytokines such as tumor necrosis factor α, interleukin 6, as well as tissue factor. Important cellular signaling pathways involved are the NF-κB-pathway, mammalian target of rapamycin (mTOR) signaling, and the NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome. All of these may serve as future therapeutic targets. Neutrophils produce neutrophil extracellular traps in response to aPL, and this leads to thrombosis. Thrombosis in APS also stems from increased interaction of neutrophils with endothelial cells through P-selectin glycoprotein ligand-1. NETosis can be targeted not only with several experimental therapeutics, such as DNase, but also through the redirection of current therapies such as defibrotide and the antiplatelet agent dipyridamole. Activation of platelets by aPL leads to a procoagulant phenotype. Platelet-leukocyte interactions are increased, possibly mediated by increased levels of soluble P-selectin and soluble CD40-ligand. Platelet-directed future treatment options involve the inhibition of several platelet receptors activated by aPL, as well as mTOR inhibition. This review discusses mechanisms underlying thromboinflammation in APS that present targetable therapeutic options, some of which may be generalizable to other thromboinflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands. Electronic address: d.salet@amsterdamumc.nl.
- Department of Internal Medicine & Radboud Institute of Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Rheumatology, Radboudumc and Sint Maartenskliniek, Nijmegen, The Netherlands.
Zitieren
APA
Salet, D. M., Bekkering, S., Middeldorp, S., & van den Hoogen, L. L. (2023). Targeting thromboinflammation in antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 21(4), 744-757. https://doi.org/10.1016/j.jtha.2022.12.002
Vancouver
Salet DM, Bekkering S, Middeldorp S, van den Hoogen LL. Targeting thromboinflammation in antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. 2023;21(4):744-757. doi:10.1016/j.jtha.2022.12.002
BibTeX
@article{Salet2023,
author = {Salet, Dorien M and Bekkering, Siroon and Middeldorp, Saskia and van den Hoogen, Lucas L},
title = {Targeting thromboinflammation in antiphospholipid syndrome},
journal = {Journal of Thrombosis and Haemostasis},
year = {2023},
volume = {21},
number = {4},
pages = {744--757},
doi = {10.1016/j.jtha.2022.12.002}
}
EUVIMED